Not yet recruitingPhase 2

Ketamine-Assisted Psychotherapy for Treatment-Resistant Depression

NCT07247006 · University of Rochester

Closed to entry

Status

Not accepting participants

Phase 2

Phase

Target enrolment

Study sites

1 US states

What it is testing

Summary

The goal of this clinical trial is to understand the effect of ketamine on the brain in people with treatment-resistant depression (TRD). TRD occurs in around a third of people with depression and leads to higher suicide rates compared to those with major depressive disorder. A desperate need for a rapid acting antidepressant drug (RAAD) is needed to help improve quality of life for people with TRD. Ketamine has been shown to be a RAAD, and esketamine (a form of ketamine) was approved by the FDA to treat TRD. Ketamine has been known to cause dissociative experiences, that can lead to an increase in the "Openness to Experience" personality trait and psychological flexibility that occurs at "peak experience". This has been shown to improve mental health conditions and lower suicide risk. This study aims to further understand if there is a connection between this new change of mind and changes in brain activity. Ketamine has been shown to improve brain plasticity as well, specifically in the frontolimbic region of the brain, an area associated with depression. The investigators are analyzing the brain using functional magnetic resonance imaging (fMRI), a method used to measure brain activity. The frontolimbic region is also associated with cognitive flexibility and emotional processing, an important hurdle in treating TRD. Due to this, the investigators are pairing the ketamine treatment with psychotherapy sessions, to guide the processing experience, which can lead to higher emotional flexibility. The main questions this study aims to answer are: * Are frontolimibic plasticity circuitry changes associated with openness to experience and peak experience? * Is it feasible to recruit and retain people through a two-month KAP study? * Is the structure of the study effective for treating TRD? Participants will: * Visit the facilities 6-8 times * Complete 2 MRI brain scans * Complete 3-4 psychotherapy sessions * Receive 1-2 doses of ketamine * Complete online surveys between 3-4 visits

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

Proportion of Participants Retained in Study Through 2-Month Follow-Up
Measured over 2 months post-enrollment
Mean Change in Hamilton Depression Rating Scale (HDRS) Total Score
Measured over Baseline, once a day for up to 7 days after baseline, within 90 minutes after ketamine dosing session, once a day for up to 7 days after ketamine dosing session, once a day up to 7 days before 2-month follow-up, and at 2-month follow-up

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years

Ages

All

Sex

Not accepted

Healthy volunteers

Inclusion Criteria The following inclusion criteria must be met for all subjects to be considered eligible to participate: 1. 18 years old or older 2. Able to speak, read, and understand English 3. In generally stable health 4. Must have treatment resistant depression, as defined as scoring in the moderate or above range on the HDRS and having failed two adequate trials of antidepressants in the last two years. Exclusion Criteria General exclusion criteria for all subjects include: 1. Uncontrolled hypertension 2. Impaired cardiac status a. Abnormal ECG report in the last month prior to screening 3. Chronic Obstructive Pulmonary Disease 4. Congenital Long QT Syndrome 5. ≥265lbs or 120kg 6. Severe obesity (BMI ≥40) 7. Increased intracranial or cerebrospinal pressure 8. Pregnancy or breastfeeding 9. Hyperthyroidism 10. Prior adverse response to ketamine, including allergic reaction 11. Symptoms of psychosis or prodromal phase 12. Severe personality disorder 13. Autistic Spectrum Disorders 14. Bipolar disorder 15. History of substance abuse, defined as a score of three or more on Drug Abuse scale (prior use of psychedelics allowed) 16. Past-year suicide attempt or ongoing ideation with intent to act 17. All exclusion criteria for magnetic resonance imaging safety: any metallic implants, brain or skull abnormalities, tattoos on large body parts, and claustrophobia. 18. Taking medications that could interact with ketamine. Examples include but are not limited to: any types of stimulants, aripiprazole, diphenhydramine, hydromorphone, escitalopram, fluoxetine, alprazolam, and sertraline. Each subject's current medications will be evaluated for interactions with ketamine before admission into the trial.

Where

1 study site

Facility	City	Region	Country
University of Rochester Medical Center	Rochester	New York	United States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07247006 on ClinicalTrials.gov →

Last updated in the registry 2026-04-23. Registry records change; this page reflects the data build of 2026-08-25.

Where this trial sits

Substance

Ketamine

Indication

Recruiting in

New York107